Debabrata Maity, postdoctoral fellow in the Hamilton Group, led a study entitled, "Peptidomimetic-Based Vesicles Inhibit Amyloid-β Fibrillation and Attenuate Cytotoxicity" in JACS, where it is featured as a supplemental cover story. Deba's co-authors include colleagues from NYU Abu Dhabi Biology, and NYU President and Chemistry Professor Andrew D. Hamilton.
Summary: A supramolecular strategy based on the assembly of oligopyrrolamide-based peptidomimetic agents into functional vesicles is identified as a potent antagonist of Aβ42 fibrillation, which is associated with the pathogenesis of Alzheimer's disease. The peptidomimetic vesicles successfully rescue cells from Aβ-assisted neurotoxicity.